Efficacy and Safety Evaluation of Human Reovirus Type 3 in Immunocompetent Animals: Racine and Nonhuman Primates

Purpose: Human reovirus type 3 has been proposed to kill cancer cells with an activated Ras signaling pathway. The purpose of this study was to investigate the efficacy of reovirus in immunocompetent glioma animal models and safety/toxicity in immunocompetent animals, including nonhuman primates. Experimental Design: Racine glioma cells 9L and RG2 were implanted s.c. or intracranially in Fisher 344 rats with or without reovirus antibodies, followed by treatment of reovirus. To study whether reovirus kills contralateral tumors in the brain and to determine viral distribution, we established an in situ dual tumor model followed by reovirus intratumoral inoculation only into the ipsilateral tumor. To evaluate neurotoxicity/safety of reovirus, Cynomolgus monkeys and immunocompetent rats were given intracranially with reovirus, and pathological examination and/or behavioral studies were done. Viral shedding and clinical biochemistry were systematically studied in monkeys. Results: Intratumorally given reovirus significantly suppressed the growth of both s.c. and intracranially tumors and significantly prolonged survival. The presence of reovirus-neutralizing antibodies did not abort the reovirus’ antitumor effect. Reovirus inhibited glioma growth intracranially in the ipsilateral but not the contralateral tumors; viral load in ipsilateral tumors was 15 to 330-fold higher than the contralateral tumors. No encephalitis or behavioral abnormalities were found in monkeys and rats given reovirus intracranially. No treatment-related clinical biochemistry changes or diffuse histopathological abnormality were found in monkeys inoculated intracranially with Good Manufacturing Practice prepared reovirus. Microscopic changes were confined to the region of viral inoculation and were dose related, suggesting reovirus intracranially was well tolerated in nonhuman primates. Conclusions: These data show the efficacy and safety of reovirus when it is used in the treatment of gliomas in immunocompetent hosts. Inoculation of reovirus into the brain of nonhuman primates did not produce significant toxicities.

[1]  K. Norman,et al.  Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer , 2004, Gene Therapy.

[2]  Rolf F. Barth,et al.  Rat brain tumor models in experimental neuro-oncology:The 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 Gliomas , 2004, Journal of Neuro-Oncology.

[3]  H. Atkins,et al.  VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. , 2003, Cancer cell.

[4]  H. Mizuguchi,et al.  Enhanced antitumor effect of combined replicative adenovirus and nonreplicative adenovirus expressing interleukin-12 in an immunocompetent mouse model , 2003, Gene Therapy.

[5]  A. García-Sastre,et al.  Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. , 2003, Cancer research.

[6]  C. Thirukkumaran,et al.  Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. , 2003, Blood.

[7]  T. Curran,et al.  Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma. , 2003, Cancer research.

[8]  J. Bristol,et al.  In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  Lawrence M Wein,et al.  Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. , 2003, Cancer research.

[10]  S. Han,et al.  Gene therapy with GM-CSF, interleukin-4 and herpes simplex virus thymidine kinase shows strong antitumor effect on lung cancer. , 2003, Anticancer research.

[11]  S. Kitano,et al.  Oncolytic viral therapy for human pancreatic cancer cells by reovirus. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  K. Norman,et al.  Systemic reovirus therapy of metastatic cancer in immune-competent mice. , 2003, Cancer research.

[13]  G. Palù,et al.  Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and herpes simplex virus thymidine kinase. , 2003, European journal of endocrinology.

[14]  Yasuo Watanabe,et al.  Restricted clinical efficacy of cyclosporin A on rat transient middle cerebral artery occlusion. , 2002, Life sciences.

[15]  K. Hirasawa,et al.  Reovirus therapy of lymphoid malignancies. , 2002, Blood.

[16]  G. Perkins,et al.  Differential Neuroprotection by Cyclosporin A and FK506 Following Ischemia Corresponds with Differing Abilities to Inhibit Calcineurin and the Mitochondrial Permeability Transition , 2002, Neurobiology of Disease.

[17]  P. Hamet,et al.  Comparisons between C57BL/6J and A/J mice in motor activity and coordination, hole-poking, and spatial learning , 2002, Brain Research Bulletin.

[18]  J. Bell,et al.  Oncolytic viruses: programmable tumour hunters. , 2002, Current gene therapy.

[19]  K. Norman,et al.  Reovirus oncolysis of human breast cancer. , 2002, Human gene therapy.

[20]  K. Norman,et al.  Oncolytic reovirus against ovarian and colon cancer. , 2002, Cancer research.

[21]  H. Xiong,et al.  Impaired Spatial Cognition and Synaptic Potentiation in a Murine Model of Human Immunodeficiency Virus Type 1 Encephalitis , 2002, The Journal of Neuroscience.

[22]  Meng Yang,et al.  Direct external imaging of nascent cancer, tumor progression, angiogenesis, and metastasis on internal organs in the fluorescent orthotopic model , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Sampson,et al.  Viruses in the treatment of malignant glioma , 2001, Current opinion in molecular therapeutics.

[24]  R. Martuza,et al.  Replication-selective virotherapy for cancer: Biological principles, risk management and future directions , 2001, Nature Medicine.

[25]  S. Nishikawa,et al.  Reovirus as an oncolytic agent against experimental human malignant gliomas. , 2001, Journal of the National Cancer Institute.

[26]  K. Norman,et al.  Oncolytic viruses and cancer therapy. , 2001, Cytokine & growth factor reviews.

[27]  R. Martuza,et al.  Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  C. Miller,et al.  Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model. , 2000, Cancer research.

[29]  G. Barber,et al.  Vesicular Stomatitis Virus (VSV) Therapy of Tumors , 2000, IUBMB life.

[30]  H. Lassmann,et al.  Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials , 1999, Nature Medicine.

[31]  D. Louis,et al.  Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses , 1999, Nature Medicine.

[32]  R. Martuza,et al.  Attenuated, Replication-Competent Herpes Simplex Virus Type 1 Mutant G207: Safety Evaluation of Intracerebral Injection in Nonhuman Primates , 1999, Journal of Virology.

[33]  Ping-An Li,et al.  Amelioration by cyclosporin A of brain damage in transient forebrain ischemia in the rat , 1998, Brain Research.

[34]  M. Coffey,et al.  Reovirus therapy of tumors with activated Ras pathway. , 1998, Science.

[35]  M. Coffey,et al.  The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus , 1998, The EMBO journal.

[36]  R. Chung,et al.  An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy , 1998, Nature Biotechnology.

[37]  J. Markert,et al.  Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins , 1998, Gene Therapy.

[38]  Y. Iwadate,et al.  Induction of acquired immunity in rats that have eliminated intracranial gliosarcoma cells by the expression of herpes simplex virus-thymidine kinase gene and ganciclovir administration. , 1997, Oncology.

[39]  C. Kramm,et al.  Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. , 1996, Human gene therapy.

[40]  G. Harsh,et al.  Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm. , 1996, Cancer gene therapy.

[41]  J. Strong,et al.  The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection , 1996, Journal of virology.

[42]  J. Park,et al.  Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. , 1994, Cancer research.

[43]  J. Strong,et al.  Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency. , 1993, Virology.

[44]  K. Tyler,et al.  Lymphocytes protect against and are not required for reovirus-induced myocarditis , 1993, Journal of virology.

[45]  Z. Ram,et al.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. , 1992, Science.

[46]  R. Sutherland,et al.  Place navigation by rats in a swimming pool. , 1984 .

[47]  H. Weiner,et al.  Age dependent susceptibility to reovirus type 3 encephalitis: Role of viral and host factors , 1983, Annals of neurology.

[48]  R. Morris,et al.  Place navigation impaired in rats with hippocampal lesions , 1982, Nature.

[49]  G. Jackson,et al.  Viruses causing common respiratory infection in man. IV. Reoviruses and Adenoviruses. , 1973, The Journal of infectious diseases.

[50]  C. Raine,et al.  REOVIRUS TYPE III ENCEPHALITIS—A VIROLOGIC AND ULTRASTRUCTURAL STUDY , 1973 .